Reversing agents for ATP-binding cassette (ABC) transporters: application in modulating multidrug resistance (MDR)
- PMID: 14754411
- DOI: 10.2174/1568011043482197
Reversing agents for ATP-binding cassette (ABC) transporters: application in modulating multidrug resistance (MDR)
Abstract
One of the main reasons for the failure in cancer chemotherapy is the existence of multidrug resistance (MDR) mechanisms. One form of MDR phenotype is contributed by a group of plasma membrane proteins that belong to a large superfamily of proteins called the ATP-binding cassette (ABC) transporters. There has been intense search for compounds, which can act at reversing MDR phenotype exhibited by ABC transporters such as P-glycoprotein (P-gp), multidrug-resistance protein (MRP) and breast cancer resistance protein (BCRP). Reversing agents can be designed to target MDR-associated ABC transporters at three levels - the protein, mRNA or DNA level. This review aims at describing, over-viewing and discussing currently known MDR reversing agents, which have been shown to act at either of the three levels against ABC transporters. Other potential agents and strategies, which can be used to reverse the MDR phenotype, are also discussed.
Similar articles
-
Multidrug resistance: molecular mechanisms and clinical relevance.Cancer Chemother Pharmacol. 1997;40 Suppl:S3-8. doi: 10.1007/s002800051053. Cancer Chemother Pharmacol. 1997. PMID: 9272126 Review.
-
Reversing agents for ATP-binding cassette drug transporters.Methods Mol Biol. 2010;596:325-40. doi: 10.1007/978-1-60761-416-6_14. Methods Mol Biol. 2010. PMID: 19949930 Review.
-
Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.Int J Cancer. 2002 Feb 20;97(6):751-60. doi: 10.1002/ijc.10131. Int J Cancer. 2002. PMID: 11857350
-
β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.Phytomedicine. 2016 Mar 15;23(3):316-23. doi: 10.1016/j.phymed.2016.01.008. Epub 2016 Feb 6. Phytomedicine. 2016. PMID: 26969385
-
Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.Curr Med Chem. 2006;13(16):1859-76. doi: 10.2174/092986706777585077. Curr Med Chem. 2006. PMID: 16842198 Review.
Cited by
-
A long non-coding RNA contributes to doxorubicin resistance of osteosarcoma.Tumour Biol. 2016 Feb;37(2):2737-48. doi: 10.1007/s13277-015-4130-7. Epub 2015 Sep 25. Tumour Biol. 2016. PMID: 26408180
-
The anti-hepatitis drug DDB chemosensitizes multidrug resistant cancer cells in vitro and in vivo by inhibiting P-gp and enhancing apoptosis.Invest New Drugs. 2007 Apr;25(2):95-105. doi: 10.1007/s10637-006-9001-z. Invest New Drugs. 2007. PMID: 16937080
-
Cooperation between prokaryotic (Lde) and eukaryotic (MRP) efflux transporters in J774 macrophages infected with Listeria monocytogenes: studies with ciprofloxacin and moxifloxacin.Antimicrob Agents Chemother. 2008 Sep;52(9):3040-6. doi: 10.1128/AAC.00105-08. Epub 2008 Jun 23. Antimicrob Agents Chemother. 2008. PMID: 18573933 Free PMC article.
-
Research and Development of Atractylodes lancea (Thunb) DC. as a Promising Candidate for Cholangiocarcinoma Chemotherapeutics.Evid Based Complement Alternat Med. 2017;2017:5929234. doi: 10.1155/2017/5929234. Epub 2017 Nov 14. Evid Based Complement Alternat Med. 2017. PMID: 29348769 Free PMC article. Review.
-
A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy.Oncotarget. 2012 Jun;3(6):640-50. doi: 10.18632/oncotarget.543. Oncotarget. 2012. PMID: 22791660 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous